PURPOSE: The prognosis for locally advanced breast cancer (LABC) patients continues to be poor, with an estimated five-year survival of only 50-60%. Preclinical data demonstrates enhanced therapeutic efficacy with liposomal encapsulation of doxorubicin combined with hyperthermia (HT). Therefore this phase I/II study was designed to evaluate the safety and efficacy of a novel neoadjuvant combination treatment of paclitaxel, liposomal doxorubicin, and hyperthermia. MATERIALS AND METHODS: Eligible patients received four cycles of neoadjuvant liposomal doxorubicin (30-75 mg/m(2)), paclitaxel (100-175 mg/m(2)), and hyperthermia. They subsequently underwent either a modified radical mastectomy or lumpectomy with axillary node dissection followed by radiation therapy and then eight cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy. RESULTS: Forty-seven patients with stage IIB-III LABC were enrolled and 43 patients were evaluable. Fourteen patients (33%) had inflammatory breast cancer. Combined (partial + complete) clinical response rate was 72% and combined pathological response rate was 60%. Four patients achieved a pathologically complete response. Sixteen patients were eligible for breast-conserving surgery. The cumulative equivalent minutes (CEM 43) at T90 (tenth percentile of temperature distribution) was significantly greater for those with a pathological response. Four-year disease-free survival was 63% (95% CI, 46%-76%) and the four-year overall survival was 75% (95% CI, 58-86%). CONCLUSIONS: Neoadjuvant therapy using paclitaxel, liposomal doxorubicin and hyperthermia is a feasible and well tolerated treatment strategy in patients with LABC. The thermal dose parameter CEM 43 T90 was significantly correlated with attaining a pathological response.
PURPOSE: The prognosis for locally advanced breast cancer (LABC) patients continues to be poor, with an estimated five-year survival of only 50-60%. Preclinical data demonstrates enhanced therapeutic efficacy with liposomal encapsulation of doxorubicin combined with hyperthermia (HT). Therefore this phase I/II study was designed to evaluate the safety and efficacy of a novel neoadjuvant combination treatment of paclitaxel, liposomal doxorubicin, and hyperthermia. MATERIALS AND METHODS: Eligible patients received four cycles of neoadjuvant liposomal doxorubicin (30-75 mg/m(2)), paclitaxel (100-175 mg/m(2)), and hyperthermia. They subsequently underwent either a modified radical mastectomy or lumpectomy with axillary node dissection followed by radiation therapy and then eight cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy. RESULTS: Forty-seven patients with stage IIB-III LABC were enrolled and 43 patients were evaluable. Fourteen patients (33%) had inflammatory breast cancer. Combined (partial + complete) clinical response rate was 72% and combined pathological response rate was 60%. Four patients achieved a pathologically complete response. Sixteen patients were eligible for breast-conserving surgery. The cumulative equivalent minutes (CEM 43) at T90 (tenth percentile of temperature distribution) was significantly greater for those with a pathological response. Four-year disease-free survival was 63% (95% CI, 46%-76%) and the four-year overall survival was 75% (95% CI, 58-86%). CONCLUSIONS: Neoadjuvant therapy using paclitaxel, liposomal doxorubicin and hyperthermia is a feasible and well tolerated treatment strategy in patients with LABC. The thermal dose parameter CEM 43 T90 was significantly correlated with attaining a pathological response.
Authors: Z Vujaskovic; J M Poulson; A A Gaskin; D E Thrall; R L Page; H C Charles; J R MacFall; D M Brizel; R E Meyer; D M Prescott; T V Samulski; M W Dewhirst Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-01 Impact factor: 7.038
Authors: M L Matteucci; G Anyarambhatla; G Rosner; C Azuma; P E Fisher; M W Dewhirst; D Needham; D E Thrall Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531
Authors: G Kong; G Anyarambhatla; W P Petros; R D Braun; O M Colvin; D Needham; M W Dewhirst Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: Z Vujaskovic; E L Rosen; K L Blackwell; E L Jones; D M Brizel; L R Prosnitz; T V Samulski; M W Dewhirst Journal: Int J Hyperthermia Date: 2003 Sep-Oct Impact factor: 3.914
Authors: Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Peter M Scarbrough; Oana I Craciunescu; Janet K Horton; Holly K Dressman; Kimberly L Blackwell; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2015-03-26 Impact factor: 3.914
Authors: Tiago R Oliveira; Paul R Stauffer; Chen-Ting Lee; Chelsea D Landon; Wiguins Etienne; Kathleen A Ashcraft; Katie L McNerny; Alireza Mashal; John Nouls; Paolo F Maccarini; Wayne F Beyer; Brant Inman; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2013-09-19 Impact factor: 3.914
Authors: Randall J Kimple; Janet K Horton; Chad A Livasy; Janiel M Shields; Julia A Lawrence; Wingkeung M Chiu; Anastasia Ivanova; David W Ollila; Lisa A Carey; Jan S Halle; Carolyn I Sartor; E Claire Dees Journal: Oncologist Date: 2012-09-24